Based on the Daiichi Sankyo Co. Ltd. stock forecast from 0 analysts, the average analyst target price for Daiichi Sankyo Co. Ltd. is not available over the next 12 months. Daiichi Sankyo Co. Ltd.’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Daiichi Sankyo Co. Ltd. is Neutral, which is based on 8 positive signals and 8 negative signals. At the last closing, Daiichi Sankyo Co. Ltd.’s stock price was JPY 4,336.00. Daiichi Sankyo Co. Ltd.’s stock price has changed by -0.16% over the past week, -5.86% over the past month and +12.13% over the last year.
No recent analyst target price found for Daiichi Sankyo Co. Ltd.
No recent average analyst rating found for Daiichi Sankyo Co. Ltd.
Company Overview Daiichi Sankyo Co. Ltd.
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation; Vanflyta, a FLT3 inhibitor for the treatment of adult patients with acute myeloid leukemia; and Injectafer, a ferric carboxymaltose injection to treat iron deficiency. It also provides Liziana and Savaysa, direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT antihypertensive agents; Nilemdo, an oral treatment which lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis/inhibitor of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications caused by bone metastasis from tumors; Tarlige for treating neuropathic pain; Venofer for the treatment of iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for COVID-19 infection, influenza infection, adsorbed cell culture-derived influenza (H5N1), measles/rubella infection, and mumps. The company has a development and sales collaboration with Merck & Co., Inc. and AstraZeneca UK Limited to develop anti-cancer drugs. Daiichi Sankyo Company, Limited was founded in 1899 and is headquartered in Tokyo, Japan. Read Less
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarc...Read More
Frequently Asked Questions About Daiichi Sankyo Co. Ltd. (4568:TSE) Stock
Stock Target Advisor's fundamental analysis for Daiichi Sankyo Co. Ltd.'s stock is Neutral.
4568:TSE stock's dividend yield is 1.28%.
Our analysis grades 4568:TSE stock's dividend yield at F. This means that 4568:TSE stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4568:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4568:TSE's stock to indicate what its average analyst target is.
4568:TSE stock's Price/Earning ratio is 35.84.
Our analysis grades 4568:TSE stock's Price / Earning ratio at F. This means that 4568:TSE stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4568:TSE may be a overvalued for its sector.
The last closing price of 4568:TSE's stock was JPY 4,336.00.
The most recent market capitalization for 4568:TSE is JPY 8,853.85B.
Unfortunately we do not have enough analyst data on 4568:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Daiichi Sankyo Co. Ltd.'s stock.
As per our most recent records Daiichi Sankyo Co. Ltd. has 18,726 Employees.
Daiichi Sankyo Co. Ltd.'s registered address is 3-5-1, Nihonbashi-honcho, Tokyo, Japan, 103-8426.
You can get more information about it from Daiichi Sankyo Co. Ltd.'s website at https://www.daiichisankyo.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low debt
The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Daiichi Sankyo Co. Ltd. (4568:TSE) Stock
Stock Target Advisor's fundamental analysis for Daiichi Sankyo Co. Ltd.'s stock is Neutral.
4568:TSE stock's dividend yield is 1.28%.
Our analysis grades 4568:TSE stock's dividend yield at F. This means that 4568:TSE stock's dividend yield is above 25% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4568:TSE may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on 4568:TSE's stock to indicate what its average analyst target is.
4568:TSE stock's Price/Earning ratio is 35.84.
Our analysis grades 4568:TSE stock's Price / Earning ratio at F. This means that 4568:TSE stock's Price/Earning ratio is above 75% of the stocks in the Drug Manufacturers - General sector in the TSE exchange.
Based on this 4568:TSE may be a overvalued for its sector.
The last closing price of 4568:TSE's stock was JPY 4,336.00.
The most recent market capitalization for 4568:TSE is JPY 8,853.85B.
Unfortunately we do not have enough analyst data on 4568:TSE's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Daiichi Sankyo Co. Ltd.'s stock.
As per our most recent records Daiichi Sankyo Co. Ltd. has 18,726 Employees.
Daiichi Sankyo Co. Ltd.'s registered address is 3-5-1, Nihonbashi-honcho, Tokyo, Japan, 103-8426.
You can get more information about it from Daiichi Sankyo Co. Ltd.'s website at https://www.daiichisankyo.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for 4568:TSE !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
